Neuland Share price Target 2025, 2026, 2027 to 2030

Do you want to know the Neuland share price target for the year 2025? Here, you will get a detailed analysis of the company’s financial performance, historical data, and price target for the year 2025, 2026, 2027, 2028, 2029, and 2030 provided by the market experts and analysts.

About Neuland Laboratories Ltd

Neuland Laboratories is a company in India that makes the important building blocks used to make medicines. Instead of making finished medicines, the company produces special ingredients called APIs that help drugs work properly. These ingredients are used by many different medicine makers all around the world. Neuland has a team of scientists who carefully check each product to make sure it is safe and of high quality.

Neuland Fundamentals

• Market Cap: ₹18,167.12Cr.
• P/E Ratio: 70.03
• Book Value: ₹1,182.30
• Dividend Yield: 0.08%
• ROE: 18.58%
• ROCE: 23.49%
• 52-Week High: ₹18,089.55
• 52-Week Low: ₹7,900

Neuland Shareholding Pattern

• Promoter: 32.68%
• FII: 21.69%
• DII: 11.97%
• Public: 33.67%
• Others: 0%

Neuland Share Price Historical Data

Neuland Share Price Target 2025

In 2025, the minimum price of Neuland shares will be ₹14,300. Over the year, it is expected to go up little by little and its maximum price could reach about ₹14,500. So, the stock may trade between ₹14,300 and ₹14,500 during the year.

Neuland Share Price Target 2026

In 2026, the minimum price of Neuland shares will be ₹16,500. Over the year, it is expected to go up little by little and its maximum price could reach about ₹17,000. So, the stock may trade between ₹16,500 and ₹17,000 during the year.

Neuland Share Price Target 2027

In 2027, the minimum price of Neuland shares will be ₹18,700. Over the year, it is expected to go up little by little and its maximum price could reach about ₹19,200. So, the stock may trade between ₹18,700 and ₹19,200 during the year.

Neuland Share Price Target 2028

In 2028, the minimum price of Neuland shares will be ₹20,800. Over the year, it is expected to go up little by little and its maximum price could reach about ₹21,200. So, the stock may trade between ₹20,800 and ₹21,200 during the year.

Neuland Share Price Target 2029

In 2029, the minimum price of Neuland shares will be ₹22,600. Over the year, it is expected to go up little by little and its maximum price could reach about ₹22,850. So, the stock may trade between ₹22,600 and ₹22,850 during the year.

Neuland Share Price Target 2030

In 2030, the minimum price of Neuland shares will be ₹23,900. Over the year, it is expected to go up little by little and its maximum price could reach about ₹24,000. So, the stock may trade between ₹23,900 and ₹24,000 during the year.

Also Read: Network 18 Share Price Target 2025, 2026, 2027 to 2030

Neuland Company Financials

In the financials section of Neuland Laboratories Ltd, we will discuss its income statement and balance sheet, so you can decide whether this stock is good for you or not for trade.

Neuland Income Statement

The company earned ₹3.28 billion this year by doing business, which is a bit less than last year. After paying all its expenses (₹1.15 billion), it had ₹278 million left as profit. That’s not as much as before, but it’s still in the green. For every ₹100 it earned, it got to keep around ₹8 as profit. The company’s earnings before tax and other costs were about ₹563 million. Even though its profits dropped, it’s still working and making money.

Neuland Balance Sheet

The company owns assets worth ₹21.80 billion—this includes everything it uses to do business. It owes ₹6.55 billion to others, and after paying those off, it still has ₹15.25 billion left as its own value, or equity. It also has ₹2.40 billion saved in cash, which is way more than before. With only 12.83 million shares, and each share valued highly, investors see this company as valuable. Even with a tough year, its base is strong and stable.

Neuland Peer Companies

The peer companies of Neuland which are in tough competition are Sun Pharmaceutical Industries, Divi’s Laboratories, Cipla, Torrent Pharmaceuticals, Dr. Reddy’s Laboratories, Mankind Pharma, Concord Biotech, Blue Jet Healthcare, Gufic Biosciences, Alivus Life Sciences, Natco Pharma, and Sai Life Sciences.

F&Q

Rishi Gupta